TRIM28 and hepatocellular carcinoma: Unlike in LC cells, where TRIM28 promotes cisplatin resistance, in HCC cells, TRIM28 promotes sensitivity to oxaliplatin treatment by binding to HMGB1 (high mobility group protein B1) and promoting ubiquitination-mediated lysosomal degradation (Wang et al., 2022).